NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

Journal Article (Journal Article)

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

Full Text

Duke Authors

Cited Authors

  • Zelenetz, AD; Gordon, LI; Chang, JE; Christian, B; Abramson, JS; Advani, RH; Bartlett, NL; Budde, LE; Caimi, PF; De Vos, S; Dholaria, B; Fakhri, B; Fayad, LE; Glenn, MJ; Habermann, TM; Hernandez-Ilizaliturri, F; Hsi, E; Hu, B; Kaminski, MS; Kelsey, CR; Khan, N; Krivacic, S; LaCasce, AS; Lim, M; Narkhede, M; Rabinovitch, R; Ramakrishnan, P; Reid, E; Roberts, KB; Saeed, H; Smith, SD; Svoboda, J; Swinnen, LJ; Tuscano, J; Vose, JM; Dwyer, MA; Sundar, H

Published Date

  • November 2021

Published In

Volume / Issue

  • 19 / 11

Start / End Page

  • 1218 - 1230

PubMed ID

  • 34781267

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2021.0054


  • eng

Conference Location

  • United States